SEGMENTED INFORMATION

3 Months Ended

Mar. 31, 2025

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 13 – SEGMENT INFORMATION

The Company determines it reportable segments based on its internal organization structure and internal management reporting used to assess and allocate resources. This information are regularly reviewed by the Company’s Chief Executive Officer who is identified as the Chief Operating Decision Maker (“CODM”). The Company consists of three operating units, BioNexus Gene Lab Corp., MRNA Scientific Sdn. Bhd. and Chemrex Corporation Sdn. Bhd. which are determined as three reportable segments, as described below. These reportable segments offer different products and services, and are managed separately because they require different technology and marketing strategies. The following describes the operations in each of the Company’s reportable segments:

·	Trading of industrial chemicals	-	Includes trading of industrial chemicals
·	Provision for genomic screening services	-	includes in commercializing proprietary blood-based diagnostic test for early disease detection
·	Investment holding	-	Investment holding

The CODM evaluates the performance of each reportable segment based on operating income and key segment-specific metrics. There are no inter-segment revenue transactions between reportable segments. Except for investment holding activities and the revenue to the overseas customers as disclosed in Note 9, the Company’s revenue and principal operations are substantially confined within Malaysia.

Pursuant to ASU 2023-07, “Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures”, the financial information concerning the Company’s reportable segments is shown as below:

Segmented Information

	Provision for genomic screening services			Trading of industrial chemicals			Investment holding			Total
	Three months period ended March 2025
REVENUE	$	3,068		$	2,134,007		$	-		$	2,137,075
COST OF REVENUE		(1,406	)		(1,792,176	)		-			(1,793,582	)
GROSS PROFIT		1,662			341,831			-			343,493
OTHER INCOME
Dividend income		-			8,934			-			8,934
Interest income		20,002			3,566			-			23,568
Fair value gain on investments in equity securities		-			4,514			-			4,514
Reversal of expected credit losses		-			25,153			-			25,153
Others		3,893			25,358			-			29,251
TOTAL OTHER INCOME		23,895			67,525			-			91,420
OPERATING EXPENSES
Sales and marketing		(27,640	)		(508,990	)		(4,065	)		(540,695	)
Research and development		(12,139	)		-			-			(12,139	)
General and administrative		(56,006	)		(125,133	)		(210,737	)		(391,876	)
Fair value loss on investments in equity securities		-			(68,497	)		-			(68,497	)
Provision for expected credit losses		-			(40,124	)		-			(40,124	)
TOTAL OPERATING EXPENSES		(95,785	)		(742,744	)		(214,802	)		(1,053,331	)
LOSS FROM OPERATIONS		(70,228	)		(333,388	)		(214,802	)		(618,418	)
FINANCE COSTS		(3,364	)		(1,502	)		(43	)		(4,909	)
LOSS BEFORE TAX		(73,592	)		(334,890	)		(214,845	)		(623,327	)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(73,592	)	$	(334,890	)	$	(214,845	)	$	(623,327	)

	Provision for genomic screening services			Trading of industrial chemicals			Investment holding			Total
	Three months period ended March 2024
REVENUE	$	3,165		$	2,378,686		$	-		$	2,381,851
COST OF REVENUE		(2,252	)		(2,014,568	)		-			(2,016,820	)
GROSS PROFIT		913			364,118			-			365,031
OTHER INCOME
Dividend income		-			8,946			-			8,946
Interest income		23,783			5,200			-			28,983
Fair value gain on investments in equity securities		-			84,785			-			84,785
Gain on disposal of investments in equity securities		-			6,181			-			6,181
Reversal of expected credit losses		-			31,752			-			31,752
Others		14,911			26,289			-			41,200
TOTAL OTHER INCOME		38,694			163,153			-			201,847
OPERATING EXPENSES
Sales and marketing		(31,105	)		(120,442	)		(2,324	)		(153,871	)
Research and development		(11,475	)		-			-			(11,475	)
General and administrative		(38,275	)		(130,421	)		(147,098	)		(315,794	)
Fair value loss on investments in equity securities		-			(44,297	)		-			(44,297	)
Provision for expected credit losses		-			(120,469	)		-			(120,469	)
TOTAL OPERATING EXPENSES		(80,855	)		(415,629	)		(149,422	)		(645,906	)
(LOSS)/PROFIT FROM OPERATIONS		(41,248	)		111,642			(149,422	)		(79,028	)
FINANCE COSTS		(1,950	)		(2,687	)		(24	)		(4,661	)
(LOSS)/PROFIT BEFORE TAX		(43,198	)		108,955			(149,446	)		(83,689	)
Tax expense		-			(20,068	)		-			(20,068	)
NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(43,198	)	$	88,887		$	(149,446	)	$	(103,757	)

	Provision for genomic screening services		Trading of industrial chemicals		Investment holding		Total
	As of March 31, 2025
Segment assets	$	2,557,978	$	6,108,859	$	813,102	$	9,479,939
Included in the measure of segment assets are:
Addition to non-current assets other than financial instruments and deferred tax assets		-		9,052		-		9,052

	As of December 31, 2024
Segment assets	$	2,652,754	$	6,788,302	$	992,792	$	10,433,848
Included in the measure of segment assets are:
Addition to non-current assets other than financial instruments and deferred tax assets		150,881		221,844		-		372,725